LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

LLY

765.17

-2.47%↓

JNJ

149.65

-0.8%↓

NVO

73.86

-0.31%↓

ABBV

185.03

-0.19%↓

UNH

301.85

-1.71%↓

Search

CytomX Therapeutics Inc

Cerrado

SectorSalud

2.32 9.43

Resumen

Variación precio

24h

Actual

Mínimo

2.29

Máximo

2.36

Métricas clave

By Trading Economics

Ingresos

4.6M

24M

Ventas

13M

51M

P/B

Media del Sector

5.125

50.857

BPA

0.27

Margen de beneficio

46.203

Empleados

119

EBITDA

4.9M

23M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+93.97% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

216M

388M

Apertura anterior

-7.11

Cierre anterior

2.32

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

CytomX Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

20 jun 2025, 18:52 UTC

Ganancias

Accenture Shares Fall on Bookings Decline, Concerns over Federal Government Contract -- 3rd Update

22 jun 2025, 23:56 UTC

Ganancias

Renesas Electronics: May Book Y250B Loss Related to Wolfspeed Restructuring in 1H

22 jun 2025, 23:55 UTC

Charlas de Mercado

Markets Wait to See if Iran's Response Will be Symbolic or Substantial -- Market Talk

22 jun 2025, 23:51 UTC

Charlas de Mercado

Oil Climbs After U.S. Attack on Iran's Nuclear Sites -- Market Talk

22 jun 2025, 23:43 UTC

Charlas de Mercado

Reasons to Believe Strait of Hormuz Will Remain Open -- Market Talk

22 jun 2025, 23:38 UTC

Charlas de Mercado

Nikkei May Fall as Middle East Uncertainty Persists -- Market Talk

22 jun 2025, 23:11 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 jun 2025, 23:11 UTC

Charlas de Mercado

Early Market Reaction to Iran Attacks Restrained -- Market Talk

22 jun 2025, 22:59 UTC

Charlas de Mercado

Gold, Silver Rise as Investors Seek Haven After Strikes on Iran -- Market Talk

22 jun 2025, 21:43 UTC

Charlas de Mercado

Australian Govt Says Supports US Strikes On Iran -- Market Talk

21 jun 2025, 08:20 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

21 jun 2025, 08:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

21 jun 2025, 08:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

20 jun 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

20 jun 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

20 jun 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

20 jun 2025, 20:13 UTC

Ganancias
Adquisiciones, fusiones, absorciones

These Stocks Moved the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20 jun 2025, 20:11 UTC

Charlas de Mercado

Natural Gas Slides in Late-Week Profit Taking -- Market Talk

20 jun 2025, 19:56 UTC

Charlas de Mercado

Crude Oil Slips to End Week -- Market Talk

20 jun 2025, 18:35 UTC

Charlas de Mercado

Warehouse Clubs Seen Growing Market Share -- Market Talk

20 jun 2025, 18:12 UTC

Charlas de Mercado

Gold Slides to Close Shortened Week -- Market Talk

20 jun 2025, 17:56 UTC

Charlas de Mercado

Baker Hughes Reports Slight Decrease in U.S. Rig Count -- Market Talk

20 jun 2025, 17:50 UTC

Ganancias
Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Tesla, Accenture, GMS, CarMax, Circle Internet, Smith & Wesson, Kroger, and More -- Barrons.com

20 jun 2025, 17:35 UTC

Adquisiciones, fusiones, absorciones

Cisco Was the Dot-Com Bust's Biggest Loser. Now It's at a 25-Year High. -- Barrons.com

20 jun 2025, 17:30 UTC

Charlas de Mercado
Ganancias

Adobe's AI Headwinds Seen Fading -- Market Talk

20 jun 2025, 17:03 UTC

Ganancias

Accenture Earnings Beat Expectations. Why the Stock Is Falling Anyway. -- Barrons.com

20 jun 2025, 16:50 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

20 jun 2025, 16:50 UTC

Charlas de Mercado
Ganancias

Accenture Seeing Companies Shift to Leapfrog Mentality -- Market Talk

20 jun 2025, 16:44 UTC

Adquisiciones, fusiones, absorciones

Meet QXO, the Upstart Building Materials Stock That May Battle Home Depot for GMS -- Barrons.com

20 jun 2025, 16:40 UTC

Charlas de Mercado
Ganancias

Accenture Can't Yet Estimate Longer Term Impact from Federal Cuts -- Market Talk

Comparación entre iguales

Cambio de precio

CytomX Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

93.97% repunte

Estimación a 12 meses

Media 4.5 USD  93.97%

Máximo 5 USD

Mínimo 3.5 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CytomX Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

3

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

0.7658 / N/ASoporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.